Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Ursodiol

Known as: Acid, Ursodeoxycholic, 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid, (3?,5?,7?)-3,7-dihydroxycholan-24-oic acid 
A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder. Also produced by the Chinese… Expand
National Institutes of Health

Related topics

Related topics

42 relations

Narrower (25)

23-methylursodeoxycholic acid24-norursodeoxycholic acid3,6-dihydroxy-6-methylcholanoic acid6-fluoro-ursodeoxycholic acid
Expand
Bile Acids and SaltsBiliary cirrhosisCholelithiasisDrug Allergy
Expand

Broader (2)

Cholagogues and CholereticsUrsodeoxycholate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
Endoplasmic reticulum (ER) stress is a key link between obesity, insulin resistance, and type 2 diabetes. Here, we provide… Expand
Is this relevant?
Review
2004
Review
2004
[Primary sclerosing cholangitis].
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and… Expand
Is this relevant?
Review
2002
Review
2002
Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
Patients with ulcerative colitis have an increased risk for colorectal neoplasia; this risk approaches 0.5% to 1% per year of… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Prevalence of Liver Disease and Contributing Factors in Patients Receiving Home Parenteral Nutrition for Permanent Intestinal Failure
During use of home parenteral nutrition, chronic abnormalities on liver function tests are reported to occur in both children and… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Ursodiol for Primary Sclerosing Cholangitis
Background There is no satisfactory medical therapy for patients with primary sclerosing cholangitis. Ursodiol (ursodeoxycholic… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.
BACKGROUND & AIMS Long-term ursodeoxycholic acid (UDCA) therapy slows the progression of primary biliary cirrhosis. This study… Expand
Is this relevant?
Highly Cited
1995
Highly Cited
1995
A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss.
BACKGROUND Previous studies have documented a high incidence of gallstone formation following gastric-bypass (GBP)-induced rapid… Expand
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.
BACKGROUND Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The… Expand
Is this relevant?
Highly Cited
1991
Highly Cited
1991
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
BACKGROUND In primary biliary cirrhosis the hepatic lesions may result, at least in part, from the intracellular accumulation of… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE